冠状动脉慢血流性心绞痛患者血清胱抑素C及髓过氧化物酶水平的变化及其相关性

doi:10.3969/j.issn.1673-8640.2018.03.001

摘要/Abstract

摘要： 目的探讨冠状动脉慢血流性心绞痛患者血清胱抑素C（Cys C）、髓过氧化物酶（MPO）水平的变化及其相关性。方法选取冠状动脉慢血流性心绞痛患者100例（心绞痛组）,依据疗效分为预后良好组（59例）和预后不良组（41例）,以100名健康体检者作为正常对照组,检测所有研究对象血清Cys C、MPO水平及校正心肌梗死溶栓试验（TIMI）血流帧数。采用Pearson相关分析评价Cys C、MPO与校正TIMI血流帧数的相关性,采用Logistic回归分析评估血清Cys C、MPO水平升高是否是冠状动脉慢血流性心绞痛患者预后不良的危险因素。结果心绞痛组血清Cys C、MPO水平及校正TIMI血流帧数均明显高于正常对照组（P<0.001）。预后良好组血清Cys C、MPO水平明显低于预后不良组（P<0.001）。相关分析显示血清Cys C、MPO水平与校正TIMI血流帧数呈正相关（r值分别为0.705、0.643,P<0.05）。Logistic回归分析显示血清Cys C、MPO升高是冠状动脉慢血流性心绞痛患者预后不良的独立危险因素[Cys C：比值比（OR） =4.125,95%可信区间（CI）3.658~4.756,P=0.000;MPO：OR=6.986,95%CI 5.356~7.967,P=0.000]。结论血清Cys C、MPO水平与冠状动脉慢血流性心绞痛的发生、发展有关,是患者预后不良的独立危险因素,动态检测Cys C、MPO水平的变化可辅助判断患者的病情和预后。

关键词: 胱抑素C, 髓过氧化物酶, 冠状动脉慢血流性心绞痛

Abstract:

bjective To investigate the changes and correlation of serum cystatin C （Cys C）and myeloperoxidase （MPO） levels in patients with coronary slow-flow angina pectoris. Methods A total of 100 patients with coronary slow-flow angina pectoris were enrolled as angina pectoris group. According to treatment efficiency,they were classified into good prognosis group （59 cases） and poor prognosis group （41 cases）. Totally,100 healthy subjects were enrolled as healthy control group. Serum Cys C and MPO levels and corrected thrombolysis in myocardial infarction（TIMI）flow frames were determined. Pearson correlation analysis was used to evaluate the correlation of serum Cys C and MPO with corrected TIMI flow frames. Logistic regression analysis was used to assess whether elevated serum Cys C and MPO levels were risk factors for poor prognosis in patients with coronary slow-flow angina pectoris. Results Serum Cys C and MPO levels and corrected TIMI flow frames in angina pectoris group were higher than those in healthy control group （P<0.001）. Serum Cys C and MPO levels in good prognosis group were lower than those in poor prognosis group （P<0.001）. Pearson correlation analysis showed that serum Cys C and MPO levels were positively correlated with corrected TIMI flow frames （r=0.705 and 0.643,P<0.05）. Logistic regression analysis showed that elevated serum Cys C and MPO levels were independent risk factors for poor prognosis [Cys C：odds ratio （OR）=4.125,95% confidence interval （CI） 3.658-4.756,P=0.000;MPO：OR=6.986,95%CI 5.356-7.967, P=0.000]. Conclusions Serum Cys C and MPO levels are related to the occurrence and development of coronary slow-flow angina pectoris,and serum Cys C and MPO are independent risk factors for poor prognosis. The dynamic determinations of serum Cys C and MPO levels can be used for evaluating the status and prognosis of patients with coronary slow-flow angina pectoris.

Key words: Cystatin C, Myeloperoxidase, Coronary slow-flow angina pectoris

中图分类号:

R446.1

伊学军, 张爱玲, 翟建新. 冠状动脉慢血流性心绞痛患者血清胱抑素C及髓过氧化物酶水平的变化及其相关性[J]. 检验医学, 2018, 33(3): 191-195.

YI Xuejun, ZHANG Ailing, ZHAI Jianxin. Changes and correlation of serum cystatin C and myeloperoxidase levels in patients with coronary slow-flow angina pectoris[J]. Laboratory Medicine, 2018, 33(3): 191-195.

图/表 6

参考文献 18

1	WANG F F,HAN J L,HE R,et al. Prognostic value of coronary artery calcium score in patients with stable angina pectoris after percutaneous coronary intervention[J]. J Geriatr Cardiol,2014,11(2): 113-119.
2	BRUNETTI N D,SALVEMINI G,CUCULO A,et al. Coronary artery ectasia is related to coronary slow flow and inflammatory activation[J]. Atherosclerosis,2014,233(2): 636-640.
3	SEN T. Coronary slow flow phenomenon leads to ST elevation myocardial infarction[J]. Korean Circ J,2013,43(3): 196-198.
4	OZDOGRU I,ZENCIR C,DOGAN A,et al. Acute effects of intracoronary nitroglycerin and diltiazem in coronary slow flow phenomenon[J]. J Investig Med,2013,61(1): 45-49.
5	王娇,刘俊. 急性冠状动脉综合征患者血清基质金属蛋白酶 2 及胱抑素 C 水平的临床意义[J]. 中华老年心脑血管病杂志,2015,17(8): 871-872.
6	危小良,陈柏荣,朱晓丽,等. 脂联素及髓样过氧化物酶与冠状动脉慢血流的相关性[J]. 中山大学学报(医学科学版),2014,35(6): 870-873.
7	张红斌,赵明,张晓明,等. 通心络胶囊对冠状动脉慢血流患者脑循环的影响[J]. 河北中医,2014,36(1): 98-100.
8	石宇杰,牛丽丽,李俊峡,等. 负荷心肌核素灌注显像联合冠状动脉 CTA 对冠状动脉慢血流的诊断价值[J]. 中国循证心血管医学杂志,2015,8(4): 527-529.
9	AKPINAR I,SAYIN M R,GURSOY Y C,et al. Plateletcrit and red cell distribution width are independent predictors of the slow coronary flow phenomenon[J]. J Cardiol,2014,63(2): 112-118.
10	张伟,孙中华,米杰,等. 冠状动脉慢血流患者危险因素分析及临床随访[J]. 中华急诊医学杂志,2014,23(2): 204-208.
11	陈治奎,姜庆军,胡万英,等. 冠状动脉慢血流的临床特点及相关因素的研究[J]. 中国现代医生,2015,53(18): 26-29.
12	WANG Q,XIE Z,ZHANG W,et al. Myeloperoxidase deletion prevents high-fat diet-induced obesity and insulin resistance[J]. Diabetes,2014,63(12): 4172-4185.
13	KATO Y.Neutrophil myeloperoxidase and its substrates:formation of specific markers and reactive compounds during inflammation[J]. J Clin Biochem Nutr,2016,58(2): 99-104.
14	张晓宁,侯超,李浩彦,等. 胱抑素C的生物学特性与心血管疾病的关联性研究[J]. 中西医结合心血管病电子杂志,2015,3(15):103-104.
15	王要鑫,刘洁云,秦雷,等. 胱抑素C与心血管疾病关系的研究进展[J]. 中国全科医学,2013,16(9):961-962.
16	谢蒂立,程标,盛勇,等. 急性冠脉综合征患者血清胱抑素C与高敏C反应蛋白水平变化及意义[J]. 山东医药,2015,55(47):17-19.
17	金艳,杨承健,徐欣,等. 冠状动脉慢血流现象与血小板功能及同型半胱氨酸水平的相关性[J]. 中国老年学杂志,2013,33(4):781-782.
18	马玲,张金国,尉希清,等. 冠状动脉慢血流综合征与血浆ET-1、TAT、hs-CRP的相关性研究[J]. 中国医师杂志,2013,15(11):1526-1529.

组别	例数	性别（男/女）	年龄（岁）	吸烟史 [例（%）]	高血压史 [例（%）]	糖尿病史 [例（%）]	高血脂史 [例（%）]	SCr （μmol/L）
心绞痛组	100	54/46	60.66±11.63	32（32.00）	59（59.00）	29（29.00）	36（36.00）	73.85±11.63
正常对照组	100	60/40	58.75±10.69	29（29.00）	48（48.00）	35（35.00）	29（29.00）	75.41±13.62
统计值		0.734	1.209	0.212	2.431	0.827	1.117	0.871
P值		0.648	0.782	0.792	0.624	0.217	0.872	0.632

组别	例数	性别（男/女）	年龄（岁）	吸烟史 [例（%）]	高血压史 [例（%）]	糖尿病史 [例（%）]	高血脂史 [例（%）]	SCr （μmol/L）
心绞痛组	100	54/46	60.66±11.63	32（32.00）	59（59.00）	29（29.00）	36（36.00）	73.85±11.63
正常对照组	100	60/40	58.75±10.69	29（29.00）	48（48.00）	35（35.00）	29（29.00）	75.41±13.62
统计值		0.734	1.209	0.212	2.431	0.827	1.117	0.871
P值		0.648	0.782	0.792	0.624	0.217	0.872	0.632

组别	例数	Cys C（mg/L）	MPO（mg/L）	校正TIMI血流帧数（帧）
心绞痛组	100	1.32±0.25	30.82±7.66	48.96±10.66
正常对照组	100	0.75±0.35	9.65±3.74	20.56±2.63
t值		13.250	24.835	25.866
P值		<0.001	<0.001	<0.001

组别	例数	Cys C（mg/L）	MPO（mg/L）	校正TIMI血流帧数（帧）
心绞痛组	100	1.32±0.25	30.82±7.66	48.96±10.66
正常对照组	100	0.75±0.35	9.65±3.74	20.56±2.63
t值		13.250	24.835	25.866
P值		<0.001	<0.001	<0.001

组别	例数	Cys C	MPO
预后良好组	59	0.92±0.25	10.33±3.85
预后不良组	41	1.62±0.35	33.55±8.96
t值		16.275	23.810
P值		<0.001	<0.001